Pharmacopeia, Inc. (ACCL) (Prev: PCOP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacopeia, Inc. (ACCL) (Prev: PCOP)

ACCL 4.050

-8.0%

Nov 4 3:58 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (109)	11/5/1998 9:09:00 AM
From: kinkblot	of 179

That looks like a very ambitious program at Triad. The approach outlined on Triad's website involves 'focusing' combinatorial libraries using structural data from their proprietary NMR SOLVE experiments. They claim this results in a >100X increase in hit rate versus random libraries, without sacrificing diversity. Whether or not any PCOP compound libraries are used in this instance, if MSI's software becomes the platform of choice for small companies like Triad, that could also lead to collaborations on the library/screening side of the business. This is one way that synergy of the PCOP/MSI merger might work from the customer's standpoint. Daniel Sem, VP for Biophysics at Triad, gives the software a nice endorsement: "MSI's integrated software solution fits well with our efforts at bringing together the cutting edge tools of NMR-structural biology, bioinformatics and combinatorial chemistry, and provides the best platform for integrating and leveraging data across these disciplines." Cerius2 Version 3.8 was released October 14. Here's a page on the C2-Diversity module from the suite of 'molecular diversity tools' for combinatorial chemistry: msi.com WT

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next